Patent application number | Description | Published |
20090074760 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. | 03-19-2009 |
20100080769 | Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies - Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen. | 04-01-2010 |
20110008250 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
20110008336 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
20110008337 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
20110008338 | Treatment of Autoimmune Diseases - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 01-13-2011 |
20120201818 | TREATMENT OF MULTIPLE SCLEROSIS - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 08-09-2012 |
20130084289 | TREATMENT OF MULTIPLE SCLEROSIS - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 04-04-2013 |
20130273039 | COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY - New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas. | 10-17-2013 |
20130273041 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients. | 10-17-2013 |
20130273042 | TREATMENT OF MULTIPLE SCLEROSIS - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 10-17-2013 |
20140030263 | TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA WITH ANTI-CD20 ANTIBODY - The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen. | 01-30-2014 |
20140056887 | COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY - New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas. | 02-27-2014 |
20140134164 | TREATMENT OF MULTIPLE SCLEROSIS - The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20. | 05-15-2014 |
20140302018 | TREATMENT OF DIFFUSE LARGE-CELL LYMPHOMA WITH ANTI-CD20 ANTIBODY - The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen. | 10-09-2014 |
20140363424 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD | 12-11-2014 |